1.中国人民解放军总医院第六医学中心中医医学部,北京市海淀区阜成路6号,100048
2.中国人民解放军医学院
通信作者:ymh9651@sina.com
收稿:2025-08-20,
修回:2025-09-27,
纸质出版:2025-12-02
移动端阅览
孙和昊,谌盈帆,王鹏等.补肾活血颗粒对帕金森病模型小鼠脑纹状体多巴胺稳态及ERK/CREB/VMAT2信号通路的影响[J].中医杂志,2025,66(23):2484-2493.
SUN Hehao,CHEN Yingfan,WANG Peng,et al.Effect of Bushen Huoxue Granule (补肾活血颗粒) on Dopamine Homeostasis and ERK/CREB/VMAT2 Signaling Pathways in the Striatum in Parkinson's Disease Model Mice[J].Journal of Traditional Chinese Medicine,2025,66(23):2484-2493.
孙和昊,谌盈帆,王鹏等.补肾活血颗粒对帕金森病模型小鼠脑纹状体多巴胺稳态及ERK/CREB/VMAT2信号通路的影响[J].中医杂志,2025,66(23):2484-2493. DOI: 10.13288/j.11-2166/r.2025.23.015.
SUN Hehao,CHEN Yingfan,WANG Peng,et al.Effect of Bushen Huoxue Granule (补肾活血颗粒) on Dopamine Homeostasis and ERK/CREB/VMAT2 Signaling Pathways in the Striatum in Parkinson's Disease Model Mice[J].Journal of Traditional Chinese Medicine,2025,66(23):2484-2493. DOI: 10.13288/j.11-2166/r.2025.23.015.
目的
2
从多巴胺稳态探讨补肾活血颗粒治疗帕金森病的可能机制。
方法
2
将72只小鼠随机分为空白组、模型组、美多芭组和补肾活血颗粒低、中、高剂量组,每组12只。除空白组外其余各组小鼠采用腹腔注射1-甲基-4-苯基-1
2
3
6-四氢吡啶(MPTP)连续7天诱导构建帕金森病小鼠模型。腹腔注射结束后次日,补肾活血颗粒低、中、高剂量组小鼠分别给予补肾活血颗粒1.25、2.5、5.0 mg/(g·d)灌胃,美多芭组小鼠给予美多芭片0.093 8 mg/(g·d)灌胃,空白组与模型组小鼠给予蒸馏水0.2 ml/10 g灌胃,均每日1次,持续14天。采用旷场实验、爬杆实验与抓力实验进行行为学评价;免疫组织化学法检测脑纹状体酪氨酸羟化酶(TH)表达;尼氏染色检测纹状体神经元数量;超高效液相色谱串联质谱法检测纹状体多巴胺(DA)与3
4-二羟基苯基乙酸(DOPAC)含量;透射电镜观察纹状体神经元突触小泡;免疫荧光检测纹状体囊泡单胺转运蛋白2(VMAT2)表达;蛋白质印迹法检测纹状体细胞外调节蛋白激酶(ERK)、磷酸化细胞外调节蛋白激酶(p-ERK)、环磷腺苷效应元件结合蛋白(CREB)、磷酸化环磷腺苷效应元件结合蛋白(p-CREB)及VMAT2蛋白水平。
结果
2
与空白组比较,模型组小鼠旷场实验总路程与平均速度下降、总静止时间增加,爬杆实验中小鼠从开始运动到头完全朝下所需的时间(T-turn)与小鼠从开始运动到木杆底部的总时间(T-total)均增加,小鼠前肢抓力下降,脑纹状体TH平均光密度值、VMAT2蛋白平均荧光强度、DA含量降低,纹状体神经元数量减少,DOPAC/DA升高,纹状体p-ERK/ERK、p-CREB/CREB与VMAT2水平降低(
P
<0.01),透射电镜结果显示纹状体神经元突触小泡数量与体积明显降低。与模型组比较,美多芭组和补肾活血低、中、高剂量组小鼠上述各指标均显著改善(
P
<0.05或
P
<0.01)。与美多芭组比较,补肾活血高剂量组纹状体DA含量、p-CREB/CREB升高(
P
<0.05)。与补肾活血低剂量组比较,补肾活血高剂量组总路程、平均速度增加,总静止时间、T-turn与T-total均降低,小鼠前肢抓力增加,脑纹状体VMAT2蛋白平均荧光强度、DA含量、p-ERK/ERK、p-CREB/CREB、VMAT2水平升高(
P
<0.05或
P
<0.01)。
结论
2
补肾活血颗粒可能通过调节ERK/CREB/VMAT2信号通路促进多巴胺稳态平衡,缓解帕金森病多巴胺能神经元损伤。
Objective
2
To investigate the possible mechanism of Bushen Huoxue Granule (补肾活血颗粒, BHG) in treating Parkinson's disease (PD) from the perspecitve of dopamine (DA) homeostasis.
Methods
2
Seventy-two mice were randomly divided into blank group, model group, madopar group and BHG low-, medium- and high-dose groups, with 12 mice in each group. Except for the blank group, all mice were administered intraperitoneal injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 7 consecutive days to induce a PD model. On the day following the injection, BHG low-, medium- and high-dose groups were administered BHG at doses of 1.25, 2.5, and 5.0 mg/(g·d) by oral gavage, respectively, while the madopar group received madopar tablets at dose of 0.093 8 mg/(g·d) by oral gavage. The blank group and the model group were given 0.2 ml/10 g of distilled water by gavage. All treatments were given once daily for 14 days. Open field test, pole climbing test and grip test were used to evaluate the behavior of mice in each group. Immunohistochemistry was used to detect the expression of tyrosine hydroxylase (TH) in striatum. Nissl staining was used to detect the activity of striatal neurons. The contents of DA and 3
4-dihydroxyphenylacetic acid (DOPAC) in striatum were detected by ultra performance liquid chromatography tandem mass spectrometry. The number and volume of synaptic vesicles were observed by transmission electron microscope. The expression of vesicular monoamine transporter 2 (VMAT2) in striatum was detected by immunofluorescence. Western Blot was used to detect the expression of extracellular signal-regulated kinase (ERK), phosphorylated ERK (p-ERK), cAMP response element-binding protein (CREB), phosphorylated CREB (p-CREB) and VMAT2 in striatum.
Results
2
Compared to the blank group, mice in the model group show
ed a significant decline in total distance and average speed in the open field test, along with an increase in total resting time; in the pole test, both the time required for the mice to turn completely downward (T-turn) and the total time taken to reach the bottom of the pole (T-total) were prolonged; forelimb grip strength was reduced; in the striatum, the mean optical density of TH, the average fluorescence intensity of VMAT2 protein, and DA content all decreased, while the number of striatal neurons was reduced, and the DOPAC/DA ratio was elevated; the levels of p-ERK/ERK, p-CREB/CREB, and VMAT2 in the striatum significantly decreased (
P
<0.01); transmission electron microscopy revealed that both the number and volume of synaptic vesicles in striatal neurons were markedly reduced. Compared to the model group, mice in the madopar group and BHG low-, medium- and high-dose groups showed significant improvements in all the above indicators (
P
<0.05 or
P
<0.01). Compared to madopar group, the BHG high-dose group exhibited increased DA content and elevated p-CREB/CREB ratio in the striatum (
P
<0.05). Compared to the BHG low-dose group, the BHG high-dose group showed increased total distance and mean velocity, decreased total resting time, T-turn, and T-total, as well as enhanced forelimb grip strength; moreover, the average fluorescence intensity of VMAT2 protein, DA content, p-ERK/ERK, p-CREB/CREB, and VMAT2 levels in the striatum were all significantly elevated (
P
<0.05 or
P
<0.01).
Conclusion
2
BHG may restore DA homeostasis and alleviate the damage of dopaminergic neurons by regulating ERK/CREB/VMAT2 signaling pathway.
雒晓东 , 李哲 , 朱美玲 , 等 . 帕金森病(颤拘病)中医临床诊疗专家共识 [J]. 中医杂志 , 2021 , 62 ( 23 ): 2109 - 2116 .
BUCHER ML , DICENT J , DUARTE HOSPITAL C , et al . Neurotoxicology of dopamine: victim or assailant ? [J]. Neurotoxicology , 2024 , 103 : 175 - 188 . doi: 10.1016/j.neuro.2024.06.001 http://dx.doi.org/10.1016/j.neuro.2024.06.001 .
BUCHER ML , BARRETT CW , MOON CJ , et al . Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson's disease [J]. NPJ Parkinsons Dis , 2020 , 6 ( 1 ): 34 .
ZHAO M , ZHOU Y , SHENG R , et al . Gastrodin relieves Parkinson's disease-related motor deficits by facilitating the MEK-dependent VMAT2 to maintain dopamine homeostasis [J]. Phytomedicine , 2024 , 132 : 155819 . doi: 10. 1016/j.phymed.2024.155819 http://dx.doi.org/10.1016/j.phymed.2024.155819 .
李绍旦 , 杨明会 , 刘毅 . 补肾活血颗粒辅助治疗对帕金森病患者脑内多巴胺神经递质及多巴胺转运蛋白的影响 [J]. 中国中西医结合杂志 , 2011 , 31 ( 5 ): 622 - 625 .
李明伟 , 杨文学 , 齐小荣 , 等 . 补肾活血颗粒治疗帕金森病非运动症状的临床研究 [J]. 中华保健医学杂志 , 2023 , 25 ( 1 ): 24 - 27 .
陈琦 , 王鹏 , 谌盈帆 , 等 . 补肾活血颗粒对帕金森病模型小鼠大脑黑质Nrf2/NLRP3炎症小体轴的影响 [J]. 中医杂志 , 2025 , 66 ( 4 ): 390 - 398 .
齐月 , 黄金泳 , 张子炜 , 等 . MPTP诱导的帕金森病小鼠模型表型特点 [J]. 神经解剖学杂志 , 2022 , 38 ( 1 ): 107 - 110 .
SANTORO M , FADDA P , KLEPHAN KJ , et al . Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease [J]. J Neurochem , 2023 , 164 ( 2 ): 121 - 142 .
魏伟 , 吴希美 , 李元建 . 药理实验方法学 [M]. 北京 : 人民卫生出版社 , 2010 : 70 - 73 .
刘燕 , 李宇轩 , 李杰 , 等 . 基于动物运动轨迹分析系统探讨旷场实验的规范化研究 [J]. 实验动物科学 , 2024 , 41 ( 5 ): 55 - 58 .
ZHANG QS , HENG Y , MOU Z , et al . Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease [J]. Acta Pharmacol Sin , 2017 , 38 ( 10 ): 1317 - 1328 .
杨明会 , 李敏 , 窦永起 , 等 . 补肾活血法治疗帕金森病的理论探讨 [J]. 中国中医基础医学杂志 , 2009 , 15 ( 11 ): 812 - 814 .
杨明会 , 李敏 , 窦永起 , 等 . 补肾活血颗粒对帕金森病患者脑内多巴胺水平的影响 [J]. 中医杂志 , 2011 , 52 ( 4 ): 299 - 302 .
谌盈帆 , 栾振先 , 李绍旦 , 等 . 补肾活血方对帕金森病模型小鼠TLR4/NF-κB信号通路的影响 [J]. 中国中西医结合杂志 , 2021 , 41 ( 3 ): 350 - 355 .
李晨 , 王鹏 , 王亮 , 等 . 补肾活血颗粒对亚急性帕金森病模型小鼠脑黑质多巴胺神经元铁死亡的影响 [J]. 中医杂志 , 2022 , 63 ( 15 ): 1463 - 1469 .
KIM S , KANG S , CHOE J , et al . A microfluidic system for investigating anticipatory medication effects on dopamine homeostasis in dopaminergic cells [J]. Anal Chem , 2023 , 95 ( 6 ): 3153 - 3159 .
TAI M , GAMIZ-ARCO G , MARTINEZ A . Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms [J]. Biochem Soc Trans , 2024 , 52 ( 3 ): 1275 - 1291 .
MULVIHILL KG . Presynaptic regulation of dopamine release: role of the DAT and VMAT2 transporters [J]. Neurochem Int , 2019 , 122 : 94 - 105 . doi: 10.1016/j.neuint.2018.11.004 http://dx.doi.org/10.1016/j.neuint.2018.11.004 .
BIOSA A , ARDUINI I , SORIANO ME , et al . Dopamine oxidation products as mitochondrial endotoxins, a potential molecular mechanism for preferential neurodegeneration in Parkinson's disease [J]. ACS Chem Neurosci , 2018 , 9 ( 11 ): 2849 - 2858 .
WANG Y , ZHANG P , CHAO Y , et al . Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines [J]. Cell Res , 2024 , 34 ( 1 ): 47 - 57 .
NAOI M , MARUYAMA W , SHAMOTO-NAGAI M , et al . Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease [J]. J Neural Transm (Vienna) , 2024 , 131 ( 6 ): 639 - 661 .
LOHR KM , MASOUD ST , SALAHPOUR A , et al . Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease [J]. Eur J Neurosci , 2017 , 45 ( 1 ): 20 - 33 .
TANG J , XU Y , LIU C , et al . PET imaging with [ 18 F]FP-(+)-DTBZ in 6-OHDA-induced partial and full unilaterally-lesioned model rats of Parkinson's disease and the correlations to the biological data [J]. Nucl Med Biol , 2020 , 90-91 : 1 - 9 . doi: 10.1016/j.nucmedbio. 2020. 08.002 http://dx.doi.org/10.1016/j.nucmedbio.2020.08.002 .
DING Y , ZHOU M , ZHENG R , et al . Feruloylated oligosaccharides ameliorate MPTP-induced neurotoxicity in mice by activating ERK/CREB/BDNF/TrkB signalling pathway [J]. Phytomedicine , 2023 , 108 : 154512 . doi: 10.1016/j.phymed.2022.154512 http://dx.doi.org/10.1016/j.phymed.2022.154512 .
GU X , LIU L , SHEN Q , et al . Photoactivation of ERK/CREB/VMAT2 pathway attenuates MPP + -induced neuronal injury in a cellular model of Parkinson's disease [J]. Cell Signal , 2017 , 37 : 103 - 114 . doi: 10.1016/j.cellsig. 2017.06.007 http://dx.doi.org/10.1016/j.cellsig.2017.06.007 .
JIN M , MATSUMOTO S , AYAKI T , et al . DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers [J]. Nat Commun , 2022 , 13 ( 1 ): 6880 .
LI C , SUN Y , YANG W , et al . Pilose antler extracts (PAEs) protect against neurodegeneration in 6-OHDA-induced Parkinson's disease rat models [J]. Evid Based Complement Alternat Med , 2019 , 2019 : 7276407 . doi: 10.1155/2019/7276407 http://dx.doi.org/10.1155/2019/7276407 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号